Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0337 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-06 |
filingDate |
2017-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2019532620-A |
titleOfInvention |
Methods and compositions related to improved human erythrocyte survival in genetically modified immunodeficient non-human animals |
abstract |
According to an aspect of the present invention, a genetically modified immunodeficient non-human animal, wherein the genome of the non-human animal macrophages and the non-human animal macrophages and A genetically modified immunodeficient non-human animal comprising a genetic modification that deficient macrophage anti-human erythrocyte activity is provided. A method for assaying the effect of a therapeutic agent envisioned in such genetically modified immunodeficient non-human animals is provided by the present invention. In one aspect, the genetically modified immunodeficient non-human animal is a Lyst null immunodeficient mouse. |
priorityDate |
2016-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |